3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
5
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoproliferative Disorders
2
Solid Tumor, Adult
1
Pyloric Stenosis, Hypertrophic
1
Nasopharyngeal Carcinoma
1
Epstein-Barr Virus Infections
1
EBV Lymphomas
1
Advanced Cancer
1
Interventions
pembrolizumab
1
otelixizumab
1
cc-486
1
brincidofovir
1
Valganciclovir
1
Carboplatin
1
Azacitidine
1
Acyclovir
1
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Epstein-Barr Virus Infections
×
Valganciclovir
×
Clear all
NCT05011058
2025-07-28
NAVAL-1
Viracta Therapeutics, Inc.
Phase 2
Terminated
102 enrolled
28 charts